Shares of Compass Pathways Plc jumped 9.0% in morning trading to $14.23 and reached an intraday 52-week high of $14.34, driven by a cluster of regulatory progress, analyst conviction, and an upcoming investor appearance. The stock move reflected company-specific news rather than broader market momentum.
Regulatory progress was front and center. The U.S. Food and Drug Administration granted Compass a rolling New Drug Application submission and review request for COMP360, citing the strength of the company’s Phase 3 data. In addition, Compass was awarded a Commissioner’s National Priority Voucher for its psilocybin therapy targeted at treatment-resistant depression. That voucher could, if applied, shorten the FDA review period to one to two months after the company submits its final NDA.
Analyst reactions have been predominantly positive following these developments. TD Cowen reiterated a Buy rating for the stock. RBC Capital raised its price target to $22.00 from $21.00 while maintaining an Outperform rating. Maxim increased its price target to $20 from $12. Morgan Stanley lifted its target to $17 from $16. These actions from multiple firms added to the near-term enthusiasm among investors.
Adding to the focus on Compass, company management is scheduled to attend the Jefferies Global Healthcare Conference on June 3, 2026. The presentation will include a fireside chat at 12:45pm ET, an engagement that can attract institutional attention and reinforce the company’s clinical and commercial narrative.
Sector-level policy moves have also provided a broader tailwind. A White House Executive Order on psychedelic treatments directs the Drug Enforcement Administration to initiate and complete a review of psychedelic therapies that have successfully completed Phase 3 trials so that rescheduling may proceed as quickly as possible. That directive has contributed to strengthened investor confidence across companies developing psychedelic therapies.
Despite the company-specific catalysts, major U.S. benchmarks offered little macro support on the day. The S&P 500 was essentially flat at -0.02%, the Dow Jones Industrial Average was down -0.31%, and the NASDAQ was slightly positive at +0.11%. Those readings underscore that Compass’s stock appreciation was driven by developments internal to the company rather than a broad market rally.
Looking ahead on the development timeline, Part B 26-week data from the COMP006 Phase 3 trial are expected in early Q3 2026. The company continues to target a final NDA submission in Q4 2026, with launch readiness planned by year-end. On the balance sheet front, Compass reported cash and cash equivalents of $466 million, which the company states supports operations into 2028.
In aggregate, the combination of an accelerating regulatory timeline, a favorable consensus among analysts, a well-funded balance sheet, and the imminent Jefferies conference appearance has created a layered set of catalysts for Compass Pathways. Those factors together helped push the stock to its highest level in over a year.
Key data and milestones noted in this report
- Stock moved up 9.0% to $14.23, intraday high $14.34.
- FDA granted rolling NDA submission and review request for COMP360 based on Phase 3 data.
- Commissioner’s National Priority Voucher awarded for psilocybin therapy in treatment-resistant depression - potential to cut review to 1-2 months after final NDA filing.
- Analyst actions: TD Cowen - Buy reiterated; RBC Capital - PT to $22 from $21 and Outperform; Maxim - PT to $20 from $12; Morgan Stanley - PT to $17 from $16.
- Management scheduled for Jefferies Global Healthcare Conference on June 3, 2026, fireside chat at 12:45pm ET.
- COMP006 Part B 26-week data expected early Q3 2026; final NDA submission targeted for Q4 2026; launch readiness by year-end.
- Cash and cash equivalents of $466 million provide runway into 2028.
This article focuses on the facts reported about Compass Pathways’ share movement and company updates, including regulatory, analyst, and financial milestones.